DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Duloxetine for Social Anxiety Disorder: Prediction of Long Term Outcome

Information source: Massachusetts General Hospital
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Anxiety Disorder

Intervention: Duloxetine (Drug); Duloxetine (Drug); Placebo (Drug)

Phase: Phase 3

Status: Completed

Sponsored by: Massachusetts General Hospital

Official(s) and/or principal investigator(s):
Naomi M Simon, MD, Principal Investigator, Affiliation: Massachusetts General Hospital

Summary

The purpose of this study is to examine the safety and efficacy of duloxetine for the treatment of social anxiety disorder.

Clinical Details

Official title: Duloxetine for Social Anxiety Disorder: Prediction of Long Term Outcome

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment

Primary outcome: Anxiety Symptoms as Assessed by Liebowitz Social Anxiety Scale

Secondary outcome: CGI-S

Detailed description: An expanding body of clinical experience and controlled trials has established the efficacy of serotonin selective reuptake inhibitors (SSRIs) and the serotonin norepinephrine reuptake inhibitor (SNRI) venlafaxine, for the treatment of social anxiety disorder, with paroxetine, sertraline and venlafaxine extended-release (XR), which are FDA approved for this indication. The newest SNRI, duloxetine, has been shown to be effective at doses of 60mg/day to 120mg/day for anxiety associated with depression, and is anticipated to be a broad spectrum agent for mood and anxiety disorders (Dunner, Goldstein, Mallinckrodt, Lu, & Detke, 2003). However, no data on the efficacy of duloxetine for Social Anxiety Disorder, nor guidance regarding time to response or predictors of response, is yet available. These questions are the focus of this proposal. This is a two phase, 24-week research study in which participants who remain symptomatic at the end of one phase (6 weeks) enter into the next phase. In phase I, all participants receive 60mg/day of duloxetine (Cymbalta) for 6 weeks. Participants who continue to have anxiety symptoms will enter the 18-week Phase II, in which they continue taking 60 mg/day of duloxetine and they will also be randomly assigned (by chance, like a flip of a coin) to receive either an additional 60mg/day of duloxetine or placebo (contains no active medication).

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Male or female outpatients > 18 years of age with a primary psychiatric diagnosis of

generalized social anxiety disorder as defined by DSM-IV criteria and an LSAS score > 50.

- Physical examination, electrocardiogram, and laboratory findings without clinically

significant abnormalities.

- Willingness and ability to comply with the requirements of the study protocol.

Exclusion Criteria:

- Patient has a history of intolerance or lack of response to a treatment trial of

duloxetine at highest tolerated dose (<120mg/day).

- Patients with acute narrow angle glaucoma.

- Pregnant women, lactating women, and women of childbearing potential who are not

using medically accepted forms of contraception (e. g., IUD, oral contraceptives, barrier devices, condoms and foam, or implanted progesterone rods stabilized for at least 3 months).

- Concurrent use of other psychotropic medications. Patients must discontinue regular

benzodiazepine or antidepressant therapy at least one week (5 weeks for fluoxetine) prior to baseline. Concomitant beta-blockers are proscribed unless prescribed for a medical indication (e. g., hypertension, at a stable daily dose for > 1 month).

- Patients with a history of failure to satisfactorily respond to >2 prior adequate

treatment trials.

- Significant personality dysfunction likely to interfere with study participation.

- Serious medical illness or instability for which hospitalization may be likely within

the next year.

- Seizure disorders with the exception of a history of febrile seizures if they

occurred during childhood, were isolated, and did not recur in adulthood.

- Concurrent psychotherapy initiated within 2 months of baseline is prohibited.

Ongoing psychotherapy of any duration directed specifically toward treatment of the social anxiety disorder is excluded. Prohibited psychotherapy includes cognitive behavioral therapy or psychodynamic therapy that focuses on exploring specific, dynamic causes of the phobic symptomatology and provides skills for their management. General supportive individual, couples, or family therapy greater than 2 months duration is acceptable.

- Diagnosis of any of the following mental disorders as defined by the DSM-IV: a

lifetime history of schizophrenia or any other psychosis, mental retardation, organic medical disorders or bipolar disorder; eating disorders in the past 6 months; alcohol or substance abuse in the past 3 months or dependence within the past 6 months.

- Entry of patients with major depression, dysthymia, panic disorder, generalized

anxiety disorder, post-traumatic stress disorder or obsessive-compulsive disorder will be permitted if the social anxiety disorder is judged to be the predominant disorder, in order to increase accrual of a clinically relevant sample.

- Patients with significant suicidal ideation (MADRS item 10 score > 3) or who have

enacted suicidal behaviors within 6 months prior to intake will be excluded from study participation and referred for appropriate clinical intervention.

Locations and Contacts

Massachusetts General Hospital, Boston, Massachusetts 02114, United States
Additional Information

Official Website for the Center for Anxiety and Traumatic Stress Disorders

Starting date: June 2004
Last updated: June 5, 2014

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017